Rx (Prescription Medicine)
Hemlibra 105毫克注射液是一种治疗血友病A的药物，有助于预防出血发作。它应按照医生的处方进行皮下注射。
Hemlibra 105毫克注射液是一种用于治疗血友病A的处方药。其活性成分是艾美赛珠单抗（emicizumab），一种双特异性单克隆抗体，旨在模拟凝血因子VIII的功能，凝血因子VIII是血液凝固必需的蛋白质。通过连接凝血因子IXa和凝血因子X，艾美赛珠单抗促进凝血酶原转化为凝血酶，从而改善血友病A患者的止血功能。该药物通过皮下注射给药，通常用于常规预防以防止出血发作。患者应严格遵循医疗服务提供者的剂量说明。务必告知医生任何既往病史，特别是血栓事件，以及您正在服用的任何其他药物。Hemlibra应在室温（20°C至25°C或68°F至77°F）下储存，并避光保存。请勿冷冻。请置于儿童接触不到的地方。
| Medicine Form | |
|---|---|
| Rx Status | |
| Medicine Type | |
| Molecule | |
| Brand Name | |
| Strength |
未库存此 exact 强度的其他品牌，因此这些是其他强度的 Emicizumab. 未经开方医生建议，请勿更改剂量。
医学审核
Renu Meena, B.Pharm
Medical Content Writer
Renu Meena is an experienced Medical Content Writer with a strong foundation in pharmacy practice. She holds a Bachelor of Pharmacy (B.Pharm) degree from Rajasthan University of Health Sciences (RUHS), Jaipur, and is registered with the Rajasthan State Pharmacy Council (Reg. No. 55661). With 4+ years of experience across clinical pharmacy and medical content development, she creates evidence-based content for medicines, diseases, and patient education. Her work is shaped by a strong understanding of pharmacovigilance and regulatory standards, including ICH guidelines, GVP modules, ICD-10/11, and safety reporting requirements. Renu focuses on making complex medical information simple, accurate, and useful for readers while maintaining high quality and compliance.
